TransBiotec: Closes on $1.0 Million Financing

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

TransBiotec, Inc. (OTC: IMLE), developers of a patented non-invasive alcohol sensing system, announced today that it has closed on $1.0 million in financing from the sale of its Series A-1 Preferred Stock to SOBRSafe LLC, a special purpose vehicle (SPV) formed to further advance SOBRSafe®, the Company’s flagship product. SOBRSafe®, currently in beta testing phase, is a potentially disruptive solution in blood alcohol detection – a touch-based technology with anticipated applications in school buses, commercial trucking fleets, facility access control and more.

This initial $1.0 million is the first tranche of a $2.0 million offering; the Company hopes to close a second tranche of up to $1.0 million within the next 90 days.

“This is a very exciting milestone for TransBiotec, and the ultimate commercialization of SOBRSafe®,” stated TransBiotec CEO Kevin Moore. “This financing is instrumental to our product’s continued development, and gives us the capital necessary to transition into pilot phase testing. We view this as the true beginning of the SOBRSafe® story, and look forward to communicating future milestones as they occur.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of TransBiotec, Inc.’s securities.



Subscribe to Medical Device News Magazine

Related Articles